Tag Archives: Top Techniques

CACHE Your Antibodies to Save Cash!

No antibody is perfect for every application, but if you’re on a budget and everything you’ve found looks about the same, here are a few things that you should consider before purchasing.

A simple way to remember this information is with the mnemonic CACHE: Citations, Application, Clonality, Host, Epitope. The more “yes” answers that can be applied to the questions below, the more likely the candidate antibody is to be successful for the experiment at hand.

1) Citations: Does the literature support the functionality of the antibody?

A good antibody will have numerous citations supporting its use. More often than not, the manufacturer will not have validated the antibody for exactly what you need. And if the goal is to do immunohistochemistry (IHC) on paraffin-embedded kidney tissue, but the manufacturer only validated the antibody for Western blotting, the literature is the best place to go to see if someone else has used a particular antibody for that purpose. Check out CiteAb for this; it is an excellent resource to compare antibodies!

2) Application: Has the antibody been validated for the desired application?

If so, make a little mental checkmark that this might be a good one! If not, consider the applications it is validated for, and compare them to your own. An antibody for Western blotting, for instance, which may recognize the target in a denatured form, might also work for immunoprecipitations. An antibody validated for flow cytometry and fluorescence-assisted cell sorting (FACS) could recognize the native form of the protein found in a tissue section.

3) Clonality: Is the clonality appropriate?

And what is the difference between monoclonal and polyclonal antibodies, anyway? Monoclonal antibodies (mAbs) are produced by a single population of B cells that is derived from a single cell, while polyclonal antibodies (pAbs) are produced by multiple B cell clones. Each has its own advantages and disadvantages. For example, monoclonal antibodies bind to a single epitope, resulting in high specificity and low background, but staining with them is easily lost if the antigen is degraded. Polyclonal antibodies, on the other hand, are resistant to this problem in that they bind to multiple epitopes. This promiscuity can also result in higher background staining, but also greater sensitivity. Choosing to use a monoclonal antibody versus a polyclonal antibody will largely depend on the target of interest and the application of the antibody.

4) Host: Is the host for the antibody different than the species of the target?

The best practice is to use an antibody raised in a host other than that of the sample species, to avoid any potential binding of the secondary antibody to endogenous immunoglobulins within the sample. Preventing cross-reactivity within the sample minimizes background staining and is a relatively simple way to ensure better results, but this is probably the least important question to consider. There are kits available to block cross-reactivity when the source of the sample is the same as the host of the antibody.

5) Epitope: Is the antigen used to raise the antibody present in your sample (or does it have significant homology)?

Multiple epitopes can be targeted within a single molecule, and antibodies can be raised against entire proteins, a protein fragment, or a particular sequence. If you are working with samples from an uncommon organism (plant biology, anyone?), you will be relying mainly on homology of your protein of interest with the epitope that the antibody targets. This is also a good place to consider your experimental conditions. As an example, FACS requires an antibody that targets an extracellular epitope so that it can bind to live cells.

These questions are not a substitute for optimizing an antibody in the lab, but they do make it much easier to choose antibodies that work, and work reasonably well, faster.

References

CiteAb – The Life Science Data Provider, 2019, www.citeab.com/. Accessed 13 September 2019.

Lipman et al. (2005) Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources. ILAR Journal 46(3):258-268.

“Polyclonal vs Monoclonal Antibodies.” Pacific Immunology, https://www.pacificimmunology.com/resources/antibody-introduction/polyclonal-vs-monoclonal-antibodies/. Accessed 13 September 2019.

“Antibody Basics.” Novus Biologicals, https://www.novusbio.com/support/general-support/antibody-basics.html. Accessed 13 September 2019.

Top Techniques: Single-Cell RNA Sequencing

Image from Papalexi E & Satija R, Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immun (2017).

As scientists ask increasingly focused and nuanced questions regarding cellular biology, the technology required to answer such questions must also become more focused and nuanced. In the last decade, we have already seen several significant paradigm shifts in how to process data in a high-throughput manner, especially for genomic and transcriptomic analyses. Microarrays gave way to next-generation sequencing, and now next-generation sequencing has moved past bulk sample analysis and onto a new frontier: single cell RNA sequencing (scRNA-Seq). First published in 2009, this technique has gained increasing traction in the last three years due to increased accessibility and decreased cost.

So, what is scRNA-Seq?

As the name suggests, this technique obtains gene expression profiles of individual cells for analysis, as opposed to comparing averaged gene expression signals between bulk samples of cells.  

When and/or why should I use scRNA-Seq compared to bulk RNA-Seq? What are its advantages and disadvantages?

The ability to examine transcriptional changes between individual cells uniquely allows researchers to define rare cell populations, to identify heterogeneity within cell populations, to investigate cell population dynamics in depth over time, or to interrogate nuances of cell signaling pathways—all at high resolution. The increased specificity and subtlety given by single-cell sequencing data benefits, for example, developmental biologists who seek to elucidate cell lineage dynamics of organ formation and function, or cancer biologists who may be searching for rare stem cell populations within tumor samples.

Practically, scRNA-Seq often requires far less input material than traditional bulk RNA-Seq (~103-104 cells per biological sample, on average). The trade-off for this downsizing advantage, however, is because of the lower input, there is often more noise in the output data that requires additional filtering. Also, as with any rising star high-throughput technique, standardized pipelines for bioinformatics processing of the raw output data are still being finalized and formalized. As the same type of growing pains occurred when bulk RNA-Seq rose to prominence, no doubt a more final consensus will also eventually be reached for scRNA-Seq.

What platforms are used for scRNA-Seq?  

The three most current and common workflows to isolate single cells for sequencing are by microplates, microfluidics, or droplets.

Microplate-based single cell isolation is carried out by laser capture of cells, for example by FACS, into wells of microplates. This approach is useful if there are known surface markers that can be used to separate cell populations of interest. It also provides the opportunity to image the plate and ensure that enough cells were isolated and that it was truly a single cell isolation. Reagents for lysing, reverse transcribing, and preparing libraries are then added to individual wells to prepare samples for sequencing.   

Microfluidics-based single cell isolation consists of a chip with a maze of miniature lanes that contain traps, which each catch a single cell as the bulk cell mixture is flowed through. Once cells are caught within the traps, reagents for each step of the sample preparation process (lysis, reverse transcription, library preparation) are flowed through the chip lanes, pushing the cell contents and subsequent intermediate materials into various chambers for preparation, followed by harvesting the final material for sequencing.

Droplet-based single cell isolation also uses microfluidics but instead of traps it involves encapsulating, within a single droplet of lysis buffer, (1) a single cell and (2) a bead linked to microparticles, which are the reagents necessary for sample preparation. The advantage of this approach is that a barcode can be assigned to the microparticles on each bead, and thus all transcripts from a single cell will be marked with the same barcode. This aspect allows pooling of prepared samples for sequencing (decreasing cost) as the cell-specific barcodes then can be used to map transcripts back to their cell of origin.

The other significant consideration for designing scRNA-Seq experiments is what sequencing method to use. Full-length sequencing provides read coverage of entire transcripts, whereas tag-based sequencing involves capture of only one end of transcripts. While the former approach allows for improved mapping ability and isoform expression analyses, the latter allows for addition of short barcodes (Unique Molecular Identifiers, UMIs) onto transcripts that assist in reducing noise and bias during data processing.    

So, which platform should­ I use?

As with most advanced techniques, determining which platform to use depends on the biological question being asked. A microplate-based platform does not accommodate high throughput analyses but does allow for specificity in what types of cells are being analyzed. So, for example, it would be a good choice for investigating gene expression changes within a rare population of cells. It also does not require particularly specialized equipment (beyond a FACS machine) and thus is a relevant choice for researchers without access to more sophisticated options. Microfluidics-based platforms are capable of more throughput than microplate-based while retaining sensitivity, but they are more expensive. Finally, droplet-based platforms provide the greatest amount of throughput but are not as sensitive. Thus, they are most appropriate for elucidating cell population composition and/or dynamics within complex tissues.

How can my scRNA-Seq data be processed, and is it different than bulk mRNA-Seq data processing?

Performing computational analysis on scRNA-Seq data follows a similar pipeline as bulk RNA-Seq, though there are specific considerations required for scRNA-Seq data processing, especially during later stages of the pipeline. One of the major considerations is significant cell-to-cell discrepancies in expression values for individual genes. This effect occurs because each cell represents a unique sequencing library, which introduces additional technical error that could confound results when comparing cell-specific (and therefore library-specific) results. This effect can be mitigated during data processing by additional normalization and correction steps, which are included in most of the publicly available scRNA-Seq processing pipelines.

Finally, the types of interpretations drawn from scRNA-Seq experiments are also technique-specific and question-dependent. Common analyses of scRNA-Seq data include clustering, psuedotime, and differential expression. While clustering is done with bulk RNA-Seq data, clustering scRNA-Seq data allows for assessing relationships between cell populations at higher resolution. This aspect is advantageous for investigating complex tissues—such as the brain—as well as for identifying rare cell populations. Given the large sizes of scRNA-Seq data sets, performing clustering of scRNA-Seq often requires dimensionality reduction (i.e. PCA or t-SNE) to make the data less noisy as well as easier to visualize. By coupling clustering results along with differential expression data, identifying gene markers for novel or rare populations is made easier. Psuedotime analysis is particularly useful for scRNA-Seq experiments investigating stages of differentiation within a tissue. Using statistical modeling paired with data reflecting a time course (for example, various developmental stages of a tissue), this analytical method tracks the transcriptional evolution of each cell and computationally orders them into a timeline of sorts, thus providing information relevant for determining lineages and differentiation states of cells in greater detail.  

Where can I do scRNA-Seq in Boston?  

Tufts Genomics Core here at Sackler has a Fluidigm C1 machine (microfluidics). Harvard Medical School (HMS) has several options for single-cell sequencing platforms. HMS Biopolymers Core also has a Fluidigm C1 system that is available for use on a for-fee, self-serve basis after training, with reagents purchased and samples prepared by the individual, as well as a 10X machine (droplet). HMS Single-Cell Core has a inDrop machine (droplet) that includes for-fee full service with faculty consultation.

What is the future for scRNA-Seq?

Bettering the way in which samples are processed and data is analyzed is a priority for scRNA-Seq experts. Specifically, ongoing work seeks to improve library preparation and sequencing efficiency. The programs used to process scRNA-Seq data are also still in flux so as to provide better normalization and correction tools for increasingly accurate data. On a larger scale, developing technology to analyze other biological aspects (genomics, epigenomics, transcriptomics) at the single cell level is of high interest, especially when considering how powerful combining these other forms of single-cell analysis with transcriptomics could be for understanding both normal and disease biology.

Resources:

  1. scRNA-Seq software packages: https://github.com/seandavi/awesome-single-cell
  2. Review of bioinformatics and computational aspects of scRNA_Seq: https://www.frontiersin.org/articles/10.3389/fgene.2016.00163/full
  3. Practical technique review: https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0467-4
  4. Start-to-finish detailed instructions on scRNA-Seq: https://hemberg-lab.github.io/scRNA.seq.course/biological-analysis.html

Top Techniques: So you want to study metabolism…

Written by Daniel Fritz and Judi Hollander

 

When studying the phenotype of a particular cell line or observing changes after cell treatment it is often desirable to establish the relative contributions of various metabolic pathways.  Agilent’s (formerly Seahorse Bioscience’s) Seahorse XF Analyzer fulfills the role of a capable, easy-to-use platform to gather important bioenergetic data, all in real time.  While this instrument has been around for roughly ten years, it had been relegated to niche fields and saw relatively little exposure.  In fact, many of you may not be aware that Tufts recently purchased one (a Seahorse XFe96, in case you were wondering)!  With more labs and fields now considering the details of cell metabolism within the framework of their research, the Seahorse XF Analyzer (or “Seahorse”, for short) has become something of a gold standard when discussing cellular metabolism profiles and nutrient preference.  With the addition of a Seahorse analyzer to Sackler, now is as good a time as any to consider adding this instrument to your toolbox.

At this point you may be thinking, “Dan, Judi, this all sounds great, but what exactly does it do?” Good question!  Let’s discuss what exactly the Seahorse XF Analyzer measures and how it does so.  Principally, the Seahorse investigates the balance of mitochondrial oxidative phosphorylation and glycolysis within a population of cells.  The instrument is loaded with a stacked double plate.  The lower plate is a relatively simple multi-well plate that the researcher seeds with the cells of study.  The cells form a monolayer along the bottom with a small volume of media on top.  The upper plate consists of probes for each well and four small-volume drug ports per well where the researcher can preload the compounds of interest in order to test the cells’ metabolic response.  The instrument is programmed to inject specific drug ports at precise times and the well-specific probes are lowered into the media to form a microchamber where pH and oxygen level within the media can be measured.  Changes in pH and oxygen level are a consequence of the cells undergoing metabolic processes in response to the drug treatment.  The analyzer can then calculate the rate of change in these parameters, resulting in Extracellular Acidification Rate (ECAR) and Oxygen Consumption Rate (OCR), respectively. These parameters are indicative of how fast glycolysis and mitochondrial oxidative phosphorylation metabolic pathways are working.

With Seahorse, the most important part of your assay will be determining what question you want to ask.  Because of its sensitivity and capabilities, it is very easy to get lost in the amount of data you are collecting.  To aid you in your research, Agilent has a variety of kits available that can answer common questions, and their representatives are more than happy to work with you to develop a custom assay to fit your needs.  Each kit supplies a pre-measured amount of certain drugs, which are injected into wells during the assay.

Questions Assay
  • Are my cells undergoing a metabolic switch?
  • How much proton efflux is due to glycolysis?
Glycolytic Rate Assay
  • How are key mitochondrial parameters changing in my cells?
Cell Mito Stress Test
  • What is the baseline metabolic phenotype of my cells?
  • What is the metabolic potential of my cells?
Cell Energy Phenotype Test
  • What type of fuel (glucose, glutamine, fatty acids) is preferred by my cells?
  • How flexible are my cells toward using other fuels when the preferred fuel is unavailable?
Mito Fuel Flex Test
  • How capable are my cells of using glycolysis when oxidative phosphorylation is blocked?
Glycolysis Stress Test

Additional information can be found at Agilent’s site: http://www.agilent.com/en-us/products/cell-analysis-(seahorse)/seahorse-analyzers?sh_0015